GlassScriptPhysician profile
Connor Joseph Comeau
NPI 1730935073
$5,868.88
in general payments reported to CMS, 2019-2025
20 companies · $4,387 in 2025
The $4,387 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,482 · 2025: $4,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,591 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,591.13 |
| Education | $277.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $936.78 | 2024-2025 | Bimzelx, Briviact |
| Abbvie INC. | $625.81 | 2024-2025 | |
| Genzyme Corporation | $569.19 | 2024-2025 | |
| Lilly USA, LLC | $554.69 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $471.20 | 2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $406.24 | 2024-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $325.52 | 2024-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $276.05 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $271.66 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $241.80 | 2024-2025 | Dupixent, Libtayo |
| Pfizer INC. | $234.80 | 2025 | |
| Organon LLC | $218.38 | 2024-2025 | Vtama |
| Amgen INC. | $190.96 | 2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $152.49 | 2024-2025 | |
| Incyte Corporation | $151.96 | 2025 | Opzelura, Opzelura |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.00 | 2025 | Cabtreo |
| Sanofi-Aventis U.S. LLC | $48.99 | 2025 | |
| Leo Pharma INC. | $28.72 | 2025 | Anzupgo |
| Johnson & Johnson Health Care Systems INC. | $24.75 | 2024 | Tremfya |
| Botanix Sb INC | $13.89 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Comeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.